Press release
Methicillin-resistant Staphylococcus aureus (MRSA) Infection Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Explore our latest breakthroughs in Methicillin-Resistant Staphylococcus Aureus Infection Research. Learn more about our innovative pipeline today! @ Methicillin-Resistant Staphylococcus Aureus Infection Pipeline Outlook [https://www.delveinsight.com/sample-request/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Methicillin-Resistant Staphylococcus Aureus Infection Pipeline Report
* In September 2024:- AbbVie- A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections. To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.
* DelveInsight's Methicillin-Resistant Staphylococcus Aureus Infection pipeline report depicts a robust space with 25+ active players working to develop 27+ pipeline therapies for Methicillin-Resistant Staphylococcus Aureus Infection treatment.
* The leading Methicillin-Resistant Staphylococcus Aureus Infection Companies such as Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others.
* Promising Methicillin-Resistant Staphylococcus Aureus Infection Therapies such as Retapamulin, Linezolid (Zyvox), Vancomycin, Nitric Oxide, Ceftaroline fosamil, Daptomycin , and others.
Stay informed about the cutting-edge advancements in Methicillin-Resistant Staphylococcus Aureus Infection Treatments. Download for updates and be a part of the revolution in care @ Methicillin-Resistant Staphylococcus Aureus Infection Clinical Trials Assessment [https://www.delveinsight.com/sample-request/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Methicillin-Resistant Staphylococcus Aureus Infection Emerging Drugs Profile
* HY-004B8b: Helperby Therapeutics
Helperby has discovered and is developing a suite of Antibiotic Resistance Breakers (ARBs). These compounds, when combined with old antibiotics, can restore the original potency against both Gram positive and Gram negative bacteria. Helperby's HY-004 project is in phase II trials for effectiveness against nasal MRSA decolonisation.
* TRL1068: Trellis Bioscience
TRL1068 is a high affinity mAb that targets the DNABII protein family; BLAST analysis has found hundreds of DNABII homologs across many bacterial species. TRL1068 is broad-spectrum, disrupting biofilm across multiple gram-positive and gram-negative bacteria species. Upon biofilm disruption, bacteria regain antibiotic susceptibility. The drug is currently in phase I stage of clinical trial evaluation to treat Methicillin-resistant Staphylococcus aureus infections. TRL1068 has received more than $5M in grant funding from the NIH to facilitate preclinical development, including multiple animal proof-of-concept experiments.
* Delpazolid (LCB01-0371): LegoChem Biosciences
Delpazolid (LCB01 0371) is an oxazolidinone derivative antibacterial therapeutic, being developed by LegoChem Biosciences to treat Tuberculosis, Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococcal infections.
Learn more about Methicillin-Resistant Staphylococcus Aureus Infection Drugs opportunities in our groundbreaking Methicillin-Resistant Staphylococcus Aureus Infection Research and development projects @ Methicillin-Resistant Staphylococcus Aureus Infection Unmet Needs [https://www.delveinsight.com/sample-request/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Methicillin-Resistant Staphylococcus Aureus Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Parenteral
* intravenous
* Subcutaneous
* Topical.
Methicillin-Resistant Staphylococcus Aureus Infection Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Discover the latest advancements in Methicillin-Resistant Staphylococcus Aureus Infection Treatment by visiting our website. Stay informed about how we're transforming the future @ Methicillin-Resistant Staphylococcus Aureus Infection Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Methicillin-Resistant Staphylococcus Aureus Infection Pipeline Report
* Coverage- Global
* Methicillin-Resistant Staphylococcus Aureus Infection Companies- Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others.
* Methicillin-Resistant Staphylococcus Aureus Infection Therapies- Retapamulin, Linezolid (Zyvox), Vancomycin, Nitric Oxide, Ceftaroline fosamil, Daptomycin, and others.
* Methicillin-Resistant Staphylococcus Aureus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Methicillin-Resistant Staphylococcus Aureus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Methicillin-Resistant Staphylococcus Aureus Infection Pipeline on our website @ Methicillin-Resistant Staphylococcus Aureus Infection Drugs and Companies [https://www.delveinsight.com/sample-request/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Methicillin-Resistant Staphylococcus Aureus Infections: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Methicillin-Resistant Staphylococcus Aureus Infections - DelveInsight's Analytical Perspective
* Mid Stage Products (Phase II)
* HY-004: Helperby therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* TRL1068: Trellis Bioscience
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* EVX B1: Evaxion Biotech
* Drug profiles in the detailed report.....
* Inactive Products
* Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
* Methicillin-Resistant Staphylococcus Aureus Infections Key Products
* Methicillin-Resistant Staphylococcus Aureus Infections- Unmet Needs
* Methicillin-Resistant Staphylococcus Aureus Infections- Market Drivers and Barriers
* Methicillin-Resistant Staphylococcus Aureus Infections- Future Perspectives and Conclusion
* Methicillin-Resistant Staphylococcus Aureus Infections Analyst Views
* Methicillin-Resistant Staphylococcus Aureus Infections Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=methicillinresistant-staphylococcus-aureus-mrsa-infection-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Methicillin-resistant Staphylococcus aureus (MRSA) Infection Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here
News-ID: 3705300 • Views: …
More Releases from ABNewswire
How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg
Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject.
Essential Platform Features for Effective Online Chemistry Tutoring
Modern chemistry tutoring…
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by…
Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
More Releases for Staphylococcus
Rise In Prevalence Of Methicillin-Resistant Staphylococcus Aureus Infections: Po …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Through 2025?
In recent times, the market size of drugs for methicillin-resistant staphylococcus aureus (MRSA) has seen continuous growth. The market, which was worth $2.35 billion in 2024, is projected to expand to $2.47 billion in…
Leading Growth Driver in the Methicillin-Resistant Staphylococcus Aureus (MRSA) …
What market dynamics are playing a key role in accelerating the growth of the methicillin-resistant staphylococcus aureus (mrsa) drugs market?
The growth of the methicillin-resistant Staphylococcus aureus drugs market is expected to be fuelled by the rise in Hospital Acquired Infections (HAIs). Patients acquire these infections while being treated at a healthcare center, usually 48 hours or more post admissions. The root causes behind HAIs include contaminated medical apparatus, lax hand…
Methicillin-Resistant Staphylococcus Aureus Testing Market Size, Share, Developm …
LP INFORMATION offers a latest published report on Methicillin-Resistant Staphylococcus Aureus Testing Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Methicillin-Resistant Staphylococcus Aureus Testing market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million…
Staphylococcus Aureus Testing Market In-Depth Market Research Report 2027
A wide range of human clinical infection caused by Staphylococcus Aureus such as Skin, soft tissue, bacteremia, infective endocarditis and others are the major infection caused by Staphylococcus Aureus. The increased use of Staphylococcus Aureus testing in the diagnosis of staph infection grow rapidly, due to the availability of the various advanced test to screen the pathogen efficiently. There is a number of tests present in the market for Staphylococcus…
Methicillin-resistant Staphylococcus Aureus Therapeutics Pipeline Analysis 2018
MRSA infection caused by specific "staph" bacteria that is often resistant to most of antibiotic treatments. S. aureus (SA) is listed as a ‘superbug’ by U.S. Centers for Disease Control and Prevention (CDC). MRSA can either be present harmlessly on the skin (colonization) or enter the body (e.g. through broken skin) and cause an infection. The study analyzed that MRSA infection therapeutics pipeline comprises approximately 52 drug candidates in different…
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Driver
Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of staphylococcus aureus, which became resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such commonly used antibiotics. Staphylococcus aureus harbors on the skin and nasal passage of about one third of the world population, which comprises around 33%, as per Centers for Disease Control and Prevention (CDC) review 2015. MRSA can be classified into two types, based on mode of infection – Hospital…
